English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

As the Labour government in the United Kingdom introduces its plans for British freedom of information legislation in a white paper, it is important to consider the issues raised by this for the regulation of medicines. In the United Kingdom, the regulation of medicines is governed currently by the 1911Official Secrets Act and 1968Medicines Act. These require all information on drug product licence applications to be treated with the utmost secrecy by the Department of Health's regulatory authority, the Medicines Control Agency, and all its expert advisory committees. Until May 1997,the official position of the British government was that confidentiality about regulation of medicines was needed to protect drug companies' commercially sensitive trade secrets so that the pharmaceutical industry continued to invest and to make medicines available in the United Kingdom.1#### Summary pointsThe existing secrecy sits uneasily with the rhetoric of the Conservative government's 1993white paper on open government, which espoused the following principles:> Open government is part of an effective democracy. Citizens must have adequate access to the information and analysis on which …

Rethinking transparency and accountability in medicines regulation in the United Kingdom